Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Inks Contract with FedMed

NEW YORK (GenomeWeb News) – CombiMatrix today announced a contract with FedMed for coverage of the Irvine, Calif.-based firm's diagnostic laboratory services.

FedMed is a national provider network and healthcare financial services firm with a preferred provider network of more than 550,000 physicians, 4,000 hospitals, and 60,000 ancillary care providers in the US. More than 40 million people have access to the network, CombiMatrix said.

CombiMatrix CEO Mark McDonough said in a statement that the contract "underscores the notion that physicians better understand the value of the services we offer their patients, particularly chromosomal microarray analysis, or CMA. We expect the recent endorsement of CMA from the American College of Obstetricians and Gynecologists to continue to drive interest in our services."

ACOG recommended CMA earlier this month as a first-line genetic test in pregnancies where ultrasound screens uncover signs of fetal abnormalities.

CombiMatrix last week completed a public offering that raised $12 million in gross proceeds.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.